H.C. Wainwright downgraded Predictive Oncology (POAI) to Neutral from Buy without a price target after the company started working with a strategic advisor to evaluate various alternatives. The firm cites the strategic uncertainties and Predictive’s financial overhang for the downgrade.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.